Outpatient oral anticancer agent utilization and costs in Manitoba from 2003 to 2016: a population-based study
- 20 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Canadian Journal of Public Health
- Vol. 112 (3), 530-540
- https://doi.org/10.17269/s41997-020-00464-6
Abstract
Intervention In April 2012, the Manitoba Home Cancer Drug Program (HCDP) was introduced to allow 100% coverage for eligible oral anticancer agents (OAA) and supportive medications for Manitobans with cancer requiring these therapies. Research questions What is the extent of use and cost of OAAs among outpatients in Manitoba from 2003/04 to 2015/16? Did the HCDP change OAA user and prescription patterns? Methods This was a retrospective, population-based study using administrative data to measure the prevalence of drug utilization over time and the impact of HCDP on OAA use and prescriptions using generalized linear models. Manitobans with cancer who filled an OAA or supportive medication covered by HCDP from 2003/04 to 2015/16 were included. Results This study included 22,393 people with cancer who filled an OAA prescription. The prevalence of OAA use increased from 222 per 100,000 to 328 per 100,000 from 2003/04 to 2015/16. Hormone therapy for breast cancer was the most common class of OAA used (increased from 154 per 100,000 to 231 per 100,000). We observed a 2.6-fold decrease in the prevalence of oral alkylating agents and a 10.7-fold increase in the prevalence of protein kinase inhibitors during the study period. The total cost of targeted OAAs per year for all Manitobans with cancer increased from $1.8 million to $19 million. Conclusion We observed an increase in OAA prevalence and the cost of oral targeted chemotherapy is high. Our findings underline the need for addressing these high-cost medications in future developments of a national drug program.Keywords
Funding Information
- Manitoba Health, Seniors and Active Living (N/A)
This publication has 23 references indexed in Scilit:
- Estimated cost of universal public coverage of prescription drugs in CanadaCMAJ : Canadian Medical Association Journal, 2015
- Patterns of use of oral anticancer treatments in France: a Retrospective Analysis of Cancer Treatments given ORally from 2004 to 2012 (Re-ACTOR study)Current Medical Research and Opinion, 2014
- Adherence and patients’ experiences with the use of oral anticancer agentsActa Oncologica, 2013
- Are community pharmacists equipped to ensure the safe use of oral anticancer therapy in the community setting? Results of a cross-country survey of community pharmacists in CanadaJournal of Oncology Pharmacy Practice, 2013
- Adherence to oral antineoplastic agents by cancer patients: definition and literature reviewEuropean Journal of Cancer Care, 2013
- Identification of risks associated with the prescribing and dispensing of oral anticancer medicines in IrelandInternational Journal of Clinical Pharmacy, 2012
- Oral anticancer agents: a prospective pilot study of a patient educational surgery run by a pharmacist and a nurseEuropean Journal of Hospital Pharmacy, 2012
- Use and costs of oral anticancer agents in the Netherlands in the period 2000–2008Pharmacoepidemiology and Drug Safety, 2011
- Overview of the changing paradigm in cancer treatment: Oral chemotherapyAmerican Journal of Health-System Pharmacy, 2007
- Oral chemotherapy safety practices at US cancer centres: questionnaire surveyBMJ, 2007